{"id":8507,"date":"2026-11-12T15:17:12","date_gmt":"2026-11-12T14:17:12","guid":{"rendered":"https:\/\/oncopeptides.com\/?post_type=news&#038;p=8507"},"modified":"2026-11-12T15:17:51","modified_gmt":"2026-11-12T14:17:51","slug":"europeiska-gliopep-projektet-levererar-starka-resultat-som-stoder-oncopeptides-fortsatta-utveckling-inom-glioblastom","status":"publish","type":"news","link":"https:\/\/oncopeptides.com\/sv\/nyheter\/europeiska-gliopep-projektet-levererar-starka-resultat-som-stoder-oncopeptides-fortsatta-utveckling-inom-glioblastom\/","title":{"rendered":"Europeiska GLIOPEP-projektet levererar starka resultat som st\u00f6der Oncopeptides fortsatta utveckling inom glioblastom"},"content":{"rendered":"<p>GLIOPEP, ett tre\u00e5rigt internationellt forskningsprojekt st\u00f6ttat av Eurostars-3 och medfinansierat av Vinnova, har slutf\u00f6rts med framg\u00e5ng.<\/p>\n<p>Inom konsortiet har Oncopeptides samarbetat med Uppsala universitet, Xenopat (Spanien) och Crown Bioscience (Nederl\u00e4nderna) f\u00f6r att utv\u00e4rdera nya peptid-l\u00e4kemedelskonjugat (PDC) mot glioblastom \u2013 en av de mest aggressiva och sv\u00e5rbehandlade formerna av hj\u00e4rncancer. Projektet etablerade kliniskt relevanta in <em>vitro-<\/em>, <em>ex vivo-<\/em> och <em>in vivo-<\/em>modeller och uppn\u00e5dde samtliga uppsatta m\u00e5l, med resultat som \u00f6vertr\u00e4ffade f\u00f6rv\u00e4ntningarna i flera studiesystem.<\/p>\n<p>Resultaten ger ett starkt prekliniskt st\u00f6d f\u00f6r Oncopeptides strategiska beslut att prioritera glioblastom som ett centralt utvecklingsomr\u00e5de p\u00e5 v\u00e4gen mot kliniska studier.<\/p>\n<p>Som tidigare kommunicerats erh\u00f6ll Oncopeptides cirka 3,3 miljoner kronor i finansiering via Eurostars-3 och Vinnova, vilket matchades med motsvarande belopp i egen medfinansiering.<\/p>\n<p><strong>Om GLIOPEP<\/strong><\/p>\n<ul data-path-to-node=\"10\">\n<li><strong>Tidsperiod<\/strong>: 3 \u00e5r<\/li>\n<li><strong>Program<\/strong>: Eurostars-3 (medfinansierat av EU och Vinnova)<\/li>\n<li><strong>Konsortium<\/strong>: Oncopeptides AB (Sverige), Uppsala universitet (Sverige), Xenopat S.L. (Spanien), Crown Bioscience (Nederl\u00e4nderna)<\/li>\n<li><strong>Fokus<\/strong>: Utv\u00e4rdering av peptid-l\u00e4kemedelskonjugat mot glioblastom<\/li>\n<li><strong>Resultat<\/strong>: Samtliga m\u00e5l uppn\u00e5dda; resultat som \u00f6vertr\u00e4ffar f\u00f6rv\u00e4ntningarna och st\u00f6der vidare avancemang mot klinisk utveckling\n<\/li>\n<\/ul>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone wp-image-8506\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/vinnova_green_payoff_eng_rgb.png\" alt=\"\" width=\"520\" height=\"112\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/vinnova_green_payoff_eng_rgb.png 604w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/vinnova_green_payoff_eng_rgb-300x65.png 300w\" sizes=\"(max-width: 520px) 100vw, 520px\" \/>   <img decoding=\"async\" class=\"alignnone wp-image-8504\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/european-partnership-co-fund-logo-stacked-colour.png\" alt=\"\" width=\"433\" height=\"147\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/european-partnership-co-fund-logo-stacked-colour.png 989w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/european-partnership-co-fund-logo-stacked-colour-300x102.png 300w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/european-partnership-co-fund-logo-stacked-colour-768x261.png 768w\" sizes=\"(max-width: 433px) 100vw, 433px\" \/>   <img decoding=\"async\" class=\"alignnone wp-image-8503\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/eureka-network-logo-horizontal-slogan-colour-light-background.png\" alt=\"\" width=\"392\" height=\"147\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/eureka-network-logo-horizontal-slogan-colour-light-background.png 800w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/eureka-network-logo-horizontal-slogan-colour-light-background-300x113.png 300w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/11\/eureka-network-logo-horizontal-slogan-colour-light-background-768x288.png 768w\" sizes=\"(max-width: 392px) 100vw, 392px\" \/><\/p>\n","protected":false},"featured_media":8509,"template":"","meta":{"_acf_changed":false},"news_categories":[373],"protected-content":[],"class_list":["post-8507","news","type-news","status-publish","has-post-thumbnail","hentry","news_categories-forskning"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news\/8507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media\/8509"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=8507"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=8507"},{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=8507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}